News &amp; Updates

Routine use of antibiotic prophylaxis does not appear to improve outcomes in children undergoing laparoscopic orchiopexy, reveals a recent study.

Two phase III induction trials have demonstrated the efficacy and safety of obefazimod, an oral, first-in-class, small molecule, for the treatment of adults with moderate-to-severe ulcerative colitis (UC).

Obefazimod hits targets in identical trials on active UC

31 Dec 2025 by

31 Dec 2025

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-November-2025

New drug applications approved by US FDA as of 1-15 November 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Lubiprostone use heightens risk of headache

Treatment with lubiprostone is associated with an increased risk of headache in adults and children, according to a recent meta-analysis.

Is there a link between IDA, cow’s milk intake, and bottle feeding?

A study from Canada demonstrates the burden of severe iron deficiency anaemia (IDA) among healthy children in the context of ongoing bottle feeding and excessive cow’s milk intake.

30 Dec 2025

Multikingdom microbial biomarker test for autism risk assessment aids earlier diagnosis & intervention

Researchers from the Chinese University of Hong Kong (CUHK) have developed the world’s first artificial intelligence (AI)–powered multikingdom microbial biomarker test for autism spectrum disorder (ASD) risk assessment. By accurately excluding ASD in low-risk cases, the test may facilitate earlier diagnosis and intervention in high-risk groups.

30 Dec 2025

From nontargeted therapy to CGRP-targeted therapy: Breakthrough in first-line migraine prevention

Migraine is a highly disabling neurological condition that profoundly affects patients’ quality of life (QoL) and productivity. Traditional first-line (1L) preventive treatments were not originally developed for migraine and are often limited by suboptimal efficacy and poor tolerability. In an interview with MIMS Doctor, Dr William Kingston of the Division of Neurology, Department of Medicine, Temerty School of Medicine, University of Toronto, Canada, discussed the emergence of calcitonin gene–related peptide (CGRP) inhibitors, including atogepant, as a significant breakthrough in migraine prevention, offering targeted, migraine[1]specific efficacy with improved tolerability.

Mitapivat improves Hb levels in paediatric patients with PK deficiency

Treatment with mitapivat increased haemoglobin (Hb) levels in children with pyruvate kinase (PK) deficiency who were not receiving regular blood transfusions, according to the ACTIVATE-Kids trial presented at ASH 2025.